Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells.

OBJECTIVE Stat 3 functions in transducing signals from the cell's surface to its nucleus and activation of gene transcription. Aberrations of Stat 3 in breast cancer have raised the possibility of its contribution to oncogenesis. Our goal was to examine ovarian cancer cell lines to determine whether Stat 3 plays a relevant role in ovarian carcinogenesis. METHODS Protein lysates were extracted from normal ovarian surface epithelial cells and malignant cells. Western blotting techniques were performed with phosphorylation-independent or phosphorylation-specific Stat 3 (tyrosine 705) antibody. Confirmation of Stat 3 activation was determined by a luciferase reporter driven by a promoter containing Stat 3-specific binding sites. Bcl-x(L) and cyclin D(1) were also analyzed by Western blotting. RESULTS MDAH 2774, OV-1063, Caov-3, and O.C. 22819 expressed high levels of phosphorylated Stat 3. In contrast, A2780 and normal ovarian surface epithelial cells had little Stat 3 phosphorylation recognized. Confirmation of persistent activation of Stat 3 activity was shown by transfection of cells with a Stat 3 luciferase reporter. Potential downstream mediators of Stat 3 including Bcl-x(L) and cyclin D(1) were also evaluated. In cells expressing activated Stat 3, high levels of both Bcl-x(L) and cyclin D(1) were detected, whereas in A2780 cells, which did not express activated Stat 3, only low levels of Bcl-x(L) and cyclin D(1) were expressed. CONCLUSIONS Constitutive activation of Stat 3 is present in ovarian cancer lines but not in normal ovarian surface epithelial cells. Activation of Stat 3 is a common event during oncogenic transformation upstream to both Bcl-x(L) and cyclin D(1). The relationship of this aberrancy of ovarian carcinoma harboring activated Stat 3 deserves further investigation.

[1]  J. Darnell,et al.  A Single Amino Acid Substitution in the v-Eyk Intracellular Domain Results in Activation of Stat3 and Enhances Cellular Transformation , 1999, Molecular and Cellular Biology.

[2]  M. Jaroszeski,et al.  Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. , 1999, Cancer research.

[3]  D. Tweardy,et al.  Granulocyte colony‐stimulating factor activates a 72‐kDa isoform of STAT3 in human neutrophils , 1998, Journal of leukocyte biology.

[4]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[5]  J. Cheng,et al.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. Jove,et al.  Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. , 1997, Cancer research.

[7]  P. Disaia,et al.  Clinical Gynecologic Oncology , 1981 .

[8]  J. Darnell,et al.  Reflections on STAT3, STAT5, and STAT6 as fat STATs. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Darnell,et al.  Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. , 1995, Annual review of biochemistry.

[10]  S. Caradonna,et al.  The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. , 1998, Gynecologic oncology.

[11]  S. Frisch,et al.  Disruption of epithelial cell-matrix interactions induces apoptosis , 1994, The Journal of cell biology.

[12]  J. Lammers,et al.  STAT3β, a Splice Variant of Transcription Factor STAT3, Is a Dominant Negative Regulator of Transcription* , 1996, The Journal of Biological Chemistry.

[13]  P. Morin,et al.  Rare Activation of the TCF/β-Catenin Pathway in Ovarian Cancer , 2000 .

[14]  R. Brown,et al.  Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. , 1998, Molecular pharmacology.

[15]  R. L. Baldwin,et al.  Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis. , 1999, Gynecologic oncology.

[16]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[17]  J. Darnell,et al.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.

[18]  J. Cheng,et al.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.

[19]  L. Sanders,et al.  Functional differences between Stat3alpha and Stat3beta , 1997, Molecular and cellular biology.

[20]  Jiayuh Lin,et al.  Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. , 2000, Anticancer research.

[21]  A. Bellacosa,et al.  Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas , 1997, International journal of cancer.

[22]  R. Jove,et al.  Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors , 1999, Oncogene.

[23]  W. Lancaster,et al.  Organotypic culture of human ovarian surface epithelial cells: A potential model for ovarian carcinogenesis , 1998, In Vitro Cellular & Developmental Biology - Animal.

[24]  N. Ragni,et al.  Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  N. Auersperg,et al.  Serial propagation of human ovarian surface epithelium in tissue culture , 1988, Journal of cellular physiology.

[26]  J. Downward,et al.  Lack of Correlation between Activation of Jun–NH2-terminal Kinase and Induction of Apoptosis after Detachment of Epithelial Cells , 1997, The Journal of cell biology.

[27]  P. Kruk,et al.  A simplified method to culture human ovarian surface epithelium. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[28]  C. Watson,et al.  Edinburgh Research Explorer Differential activation of STATs 3 and 5 during mammary gland development , 2022 .

[29]  D. Bodurka,et al.  Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus. , 1999, Gynecologic oncology.

[30]  C. Geisler,et al.  Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells , 1999, Leukemia.

[31]  R. Jove,et al.  STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. , 1999, Current opinion in oncology.

[32]  T. Orfeo,et al.  One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. , 1977, Journal of the National Cancer Institute.

[33]  C. S. Zong,et al.  Stat3 Plays an Important Role in Oncogenic Ros- and Insulin-like Growth Factor I Receptor-induced Anchorage-independent Growth* , 1998, The Journal of Biological Chemistry.

[34]  P. Heinrich,et al.  Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level , 1993, Molecular and cellular biology.

[35]  C. Hu,et al.  Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. , 1998, Gynecologic oncology.

[36]  J. Darnell,et al.  Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.

[37]  J. Turkson,et al.  Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation , 1998, Molecular and Cellular Biology.

[38]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[39]  Z. Fuks,et al.  A new human ovarian carcinoma cell line: establishment and analysis of tumor-associated markers. , 1985, Oncology.

[40]  N. Danial,et al.  Jak-STAT signaling induced by the v-abl oncogene. , 1995, Science.

[41]  J. Darnell,et al.  Stat3 and Stat4: members of the family of signal transducers and activators of transcription. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Watson,et al.  Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. , 1995, British Journal of Cancer.

[43]  D. Tweardy,et al.  Stat3 and G-CSF-induced myeloid differentiation. , 1998, Leukemia & lymphoma.

[44]  R. Jove,et al.  Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[45]  T. Hirano,et al.  STAT3 orchestrates contradictory signals in cytokine‐induced G1 to S cell‐cycle transition , 1998, The EMBO journal.

[46]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[47]  M. Winker,et al.  Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. , 1985, Cancer research.

[48]  J. Foekens,et al.  Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours. , 1996, British Journal of Cancer.

[49]  B. Ponder,et al.  Overexpression of cyclin D1 in epithelial ovarian cancers. , 1997, Gynecologic oncology.

[50]  J. Turchi,et al.  Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines. , 1997, Cancer research.

[51]  S. Goff,et al.  Direct Interaction of Jak1 and v-Abl Is Required for v-Abl-Induced Activation of STATs and Proliferation , 1998, Molecular and Cellular Biology.